A Schedule 13G was filed on November 16, 2026, by American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research, disclosing beneficial ownership positions in the common stock of Rigel Pharmaceuticals, Inc. as of September 30, 2026.
Key Highlights
- Triggering event date: The filing reports a date of event of September 30, 2026.
- American Century ETF Trust position: The trust reported sole voting and sole dispositive power over 991,858 shares, representing 5.3% of the class.
- American Century Investment Management position: ACIM reported sole voting and sole dispositive power over 1,043,966 shares, representing 5.6% of the class.
- Parent and control person positions: American Century Companies, Inc. and Stowers Institute for Medical Research each also reported beneficial ownership of 1,043,966 shares, or 5.6% of the class.
- No shared voting or dispositive power: All four reporting persons reported 0.00 shares with shared voting power and 0.00 shares with shared dispositive power.
- Ordinary course certification: Each signing party certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
American Century Entities Report Rigel Pharmaceuticals Stakes at September 30, 2026
According to the filing, four affiliated entities jointly submitted a Schedule 13G with respect to common stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), whose principal offices are located at 611 Gateway Boulevard, Suite 900, San Francisco, California, 94080. The filing was submitted on November 16, 2026, covering a date of event of September 30, 2026. All four reporting persons are organized under the laws of Delaware and share a principal business address at 4500 Main Street, 9th Floor, Kansas City, Missouri 64111.
The filing discloses that American Century ETF Trust holds 991,858 shares with sole voting and sole dispositive power, equal to 5.3% of the class. American Century Investment Management, Inc. (ACIM), classified as an investment adviser, holds 1,043,966 shares with sole voting and sole dispositive power, representing 5.6% of the class. The filing identifies ACIM as a wholly-owned subsidiary of American Century Companies, Inc. (ACC), which in turn is controlled by Stowers Institute for Medical Research. Both ACC and Stowers Institute each separately reported beneficial ownership of 1,043,966 shares, also representing 5.6% of the class, reflecting their respective roles as parent holding company and control person.
The filing further states that "various persons, including the investment companies and separate institutional investor accounts that American Century Investment Management, Inc. serves as investment adviser, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that are the subject of this schedule." The filing adds that "not more than 5% of the class of securities that is the subject of this schedule is owned by any one client advised by ACIM." The statement was signed by John Pak, Senior Vice President, on behalf of American Century ETF Trust and American Century Investment Management, Inc., dated November 16, 2026.
What Was Disclosed
Four affiliated American Century entities filed a Schedule 13G disclosing beneficial ownership in Rigel Pharmaceuticals common stock as of September 30, 2026. American Century Investment Management, American Century Companies, and Stowers Institute each reported 1,043,966 shares (5.6%), while American Century ETF Trust reported 991,858 shares (5.3%).




Please wait processing your request...